
New Data: DecisionDx®-SCC Outperforms BWH Staging for High-Risk Skin Cancer Treatment
Castle Biosciences, Inc. (Nasdaq: CSTL), a company focused on improving health through innovative diagnostic tests, announced new data showing that its DecisionDx-SCC test offers clinically significant risk stratification for high-risk SCC patients, particularly those with suppressed immune systems. This enhanced…












